Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note released on Monday,Benzinga reports. They currently have a $46.00 price objective on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Anavex Life Sciences in a report on Monday, November 4th.

Anavex Life Sciences Price Performance

Shares of NASDAQ AVXL opened at $9.13 on Monday. The company has a 50-day moving average price of $6.46 and a 200-day moving average price of $5.58. The stock has a market capitalization of $774.22 million, a P/E ratio of -18.26 and a beta of 0.60. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $10.45.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of Anavex Life Sciences during the 2nd quarter worth approximately $57,000. Orion Capital Management LLC increased its position in shares of Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 10,000 shares during the last quarter. PVG Asset Management Corp bought a new stake in Anavex Life Sciences during the third quarter worth $74,000. Atria Investments Inc purchased a new position in Anavex Life Sciences in the third quarter worth $76,000. Finally, Fiduciary Alliance LLC grew its stake in Anavex Life Sciences by 45.2% in the 2nd quarter. Fiduciary Alliance LLC now owns 19,275 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,000 shares during the period. 31.55% of the stock is owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.